Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep 1;101(5):774-81.
doi: 10.1038/sj.bjc.6605199.

MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53

J A Canner  1 , M Sobo, S Ball, B Hutzen, S DeAngelis, W Willis, A W Studebaker, K Ding, S Wang, D Yang, J Lin
Affiliations

MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53

J A Canner et al. Br J Cancer. .

Abstract

Background: Interruption of the role of p53s as a tumour suppressor by MDM2 may be one of the mechanisms by which cancer cells evade current therapy. Blocking the inhibition of wild-type p53 by MDM2 in cancer cells should reactivate p53's tumour suppressor functions and enhance current cancer treatments. MI-63 is a novel non-peptide small molecule that has shown strong binding affinity (K(i)=3 nM) for MDM2; however, its effects on paediatric cancer cells and the specific mechanism of tumour suppressor reactivation have not been evaluated.

Methods: Rhabdomyosarcoma (RMS), the most common childhood soft tissue sarcoma, expresses either wild-type or mutant p53 protein. We examined the inhibitory effects of MI-63 in embryonal RMS (ERMS) and alveolar RMS (ARMS) cell lines expressing wild-type or mutated p53.

Results: Treatment with MI-63 reduced cell viability by 13.4% and by <1%, respectively, at 72 h in both RH36 and RH18 cell lines expressing wild-type p53. In contrast, RH30 and RD2 cells expressing p53 mutants are resistant to MI-63 treatment. An increased expression of p53, p21(WAF1), and Bax protein was observed after treatment with MI-63 in RMS cells with wild-type p53, and apoptosis was confirmed by cleaved PARP and caspase-3 expression. However, RD2 and RH30 RMS cells, as well as human normal skeletal muscle cells, showed a minimal increase in p53 signalling and no induction of cleaved PARP and caspase-3. MI-63 was compared with Nutlin-3, a known MDM2 inhibitor, and was found to be more potent in the inhibition of cell proliferation/viability. Further, synergy was observed when MI-63 was used in combination with doxorubicin.

Conclusion: These results indicate that MI-63 is a potent therapeutic agent for RMS cells expressing wild-type p53 protein.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structure of MI-63.
Figure 2
Figure 2
MI-63 treatments of HCT-116 p53 +/+ and HCT-116 p53 −/− cells. (A) MTT analysis indicates decreased cell proliferation with MI-63 in cells with wild-type p53. (B) A measure of 50 μg of total protein from HCT-116 cell lysates was subjected to SDS polyacrylamide gel electrophoresis (PAGE) and transferred to PVDF membrane. Membranes were blotted with p53, p21WAF1, cleaved caspase-3, and GAPDH antibodies.
Figure 3
Figure 3
The effect of MI-63 on the cell viability of ERMS/ARMS cells. (A, B) Rhabdomyosarcoma cells with wild-type p53, RH36 and RH18, showing decreased cell proliferation when treated with MI-63. (C, D) Rhabdomyosarcoma cells with mutated p53, RD2 and RH30, showing decreased cell proliferation when treated with MI-63.
Figure 4
Figure 4
Baseline levels of MDM2 and p53 expression in wild-type p53, RH18 and RH36, and mutant p53, RH30 and RD2, rhabdomyosarcoma cells.
Figure 5
Figure 5
The effect of MI-63 on p53 half-life in RH36 cells. Blocking MDM2 activity inhibits p53 degradation resulting in an increased p53 half-life.
Figure 6
Figure 6
Western blot analysis of ERMS/ARMS cells treated with MI-63. (A, B) Rhabdomyosarcoma cells with wild-type p53, RH36 and RH18, indicate increased p53, downstream targets, p21WAF1 and Bax, as well as cleaved caspase-3 and cleaved PARP, at 20, 30, and 40 h after treatment with 10 μM of MI-63. (C, D) Rhabdomyosarcoma cells with mutated p53, RD2 and RH30, indicate no increase of p53, downstream target p21WAF1, cleaved caspase-3, and cleaved PARP at 24 and 36 h after treatment with 10 μM of MI-63.
Figure 7
Figure 7
MI-63 treatments of HSMM cells. (A) MTT analysis shows minimal changes in cell proliferation when normal human skeletal muscle cells (HSMM) are treated with MI-63. (B) Western blot analysis of HSMM cells grown in SkBM-2 medium with growth factors. (C) Western blot analysis of HSMM cells grown in DMEM supplemented with 10% FBS. A measure of 50 μg of total protein from HSMM cell lysates was subjected to SDS PAGE and transferred to PVDF membrane. Membranes were blotted with p53, p21WAF1, Bax, cleaved caspase-3, cleaved PARP, and GAPDH antibodies. The results show an increase in p53 protein and p21WAF1 at higher doses and prolonged exposure; however, there is no apparent reactivation of apoptosis.
Figure 8
Figure 8
A comparison of the effects of MI-63 and Nutlin-3 on the viability of RH36 cells. Treatment with MI-63 results in a greater decrease in cell proliferation/viability.
Figure 9
Figure 9
Inhibition of cellular proliferation in RH-36 cells by treatment with (A) doxorubicin, (B) MI-63, or (C) a combination of both, as measured by MTT analysis. (D) A CI-effect plot: CI values calculated from proliferation experiments were plotted against the effects (fa) of five different concentrations of the drugs.
See this image and copyright information in PMC

References

    1. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21: 78–84 - PubMed
    1. Chen J, Lin J, Levine AJ (1995) Regulation of transcription functions of the p53 tumor suppressor by the MDM-2 oncogene. Mol Med 1: 142–152 - PMC - PubMed
    1. Chen J, Wu X, Lin J, Levine AJ (1996) mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445–2452 - PMC - PubMed
    1. Chene P (2004) Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. Mol Cancer Res 2: 20–28 - PubMed
    1. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55 - PubMed

MeSH terms